An­thrax-tar­get­ed biode­fense biotechs join forces in merg­er pact

Three years af­ter the biode­fense biotech Phar­ma­Th­ene’s $PIP deal to merge in­to Ther­a­clone fell apart, the An­napo­lis, MD-based group has struck a deal to com­bine with No­var­tis-backed Al­tim­mune in near­by Gaithers­burg.

Al­tim­mune share­hold­ers will come out with the li­on’s share of the stock and Al­tim­mune CEO Bill En­right takes the helm of the merged op­er­a­tion, which brings to­geth­er pro­grams with shared tar­gets. The biotech will al­so switch its stock sym­bol to $ALT.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.